 |
|
Targeted therapy of ovarian cancer including immune check point inhibitor
Jin Young Kim, Chi Heum Cho, Hong Suk Song
Korean J Intern Med. 2017;32(5):798-804. Published online 2017 Aug 22 DOI: https://doi.org/10.3904/kjim.2017.008
|
|
Citations to this article as recorded by
 Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems
Emily Tomas, Trevor G. Shepherd
Journal of Ovarian Research.2023;[Epub] CrossRef A combined network pharmacology and molecular biology approach to investigate the potential mechanisms of G-M6 on ovarian cancer
Meng Ding, Cuifang Dong, Yufeng Mao, Shuheng Liu, Yuqing Zhao, Xude Wang
Bioorganic Chemistry.2023; 138: 106657. CrossRef Expression of Enhancer-Binding Protein CEBPA mRNA and Protein in Ovarian Cancer and Its Relationship With Pathobiological Characteristics
Shufang Mi, Limei Zhang, Mo Li, Zhiting Dong, Chenchen Tian, Minwen Fu
Frontiers in Surgery.2022;[Epub] CrossRef CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy
Marisol Salgado-Albarrán, Julian Späth, Rodrigo González-Barrios, Jan Baumbach, Ernesto Soto-Reyes
npj Systems Biology and Applications.2022;[Epub] CrossRef The Effect of Bone Marrow Mesenchymal Stem Cells-Exosomes (BMSC-EXO) on Tumor Angiogenesis and Its Mechanism in Ovarian Cancer Microenvironment
Hongli Huang, Min Cheng, Xialing Zhu
Journal of Biomaterials and Tissue Engineering.2022; 12(6): 1087. CrossRef Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer
Young Joo Lee, Sung Wook Kim, Min Hyung Jung, Young Sun Kim, Kyung Sook Kim, Dong Soo Suh, Ki Hyung Kim, Eun Ha Choi, Jongmin Kim, Byung Su Kwon
Free Radical Biology and Medicine.2022; 182: 276. CrossRef The impact of the modified frailty index on clinical outcomes for patients with stage IV non-small cell lung cancer receiving chemotherapy
Shivani Mathur, Laura Prince, Oliver Bucher, Lin Xue, Shantanu Banerji, David E. Dawe
Journal of Geriatric Oncology.2022; 13(5): 654. CrossRef NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer
Sarah M Konrad, Kristina Schwamborn, Achim Krüger, Katja Honert, Manfred Schmitt, Daniela Hellmann, Barbara Schmalfeldt, Alfons Meindl, Marion Kiechle, Anne S Quante, Christine Brambs, Sabine Grill, Juliane Ramser
Biomarkers in Medicine.2022; 16(14): 1029. CrossRef miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer
Shujun Cao, Na Li, Xihong Liao
Journal of Ovarian Research.2021;[Epub] CrossRef G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients
Patricia Fraungruber, Till Kaltofen, Sabine Heublein, Christina Kuhn, Doris Mayr, Alexander Burges, Sven Mahner, Philipp Rathert, Udo Jeschke, Fabian Trillsch
Frontiers in Endocrinology.2021;[Epub] CrossRef LncRNA ARAP1-AS1 aggravates the malignant phenotypes of ovarian cancer cells through sponging miR-4735-3p to enhance PLAGL2 expression
Cuiping Li, Bing Dong, Xiaomeng Xu, Yuewen Li, Yan Wang, Xingmei Li
Cytotechnology.2021; 73(3): 363. CrossRef Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation
Zhigao Niu, Wenping Zhang, Jialun Shi, Xiangdong Li, Hanlei Wu
Journal of Cardiothoracic Surgery.2021;[Epub] CrossRef Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer
Shini Liu, Qiong Zou, Jie-Ping Chen, Xiaosai Yao, Peiyong Guan, Weiting Liang, Peng Deng, Xiaowei Lai, Jiaxin Yin, Jinghong Chen, Rui Chen, Zhaoliang Yu, Rong Xiao, Yichen Sun, Jing Han Hong, Hui Liu, Huaiwu Lu, Jianfeng Chen, Jin-Xin Bei, Joanna Koh, Jas
Journal of Clinical Investigation.2021;[Epub] CrossRef Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
Pascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, Andreas Schlicker, Anne Mobergslien, Lisa Bartnitzky, Sandra Berndt, Sabine Zitzmann-Kolbe, Claudia Kamfenkel, Stefan Stargard, Stefanie Hammer, Jennifer S Jørgensen, Malene Jackerott, Carsten H Niels
Journal for ImmunoTherapy of Cancer.2021; 9(10): e002387. CrossRef Chitosan is a potential inhibitor of ovarian cancer: Molecular aspects
Maryam Chamani, Parisa Maleki Dana, Shahla Chaichian, Bahram Moazzami, Zatollah Asemi
IUBMB Life.2020; 72(4): 687. CrossRef Sensitive competitive label-free electrochemical immunosensor for primal detection of ovarian cancer
Saima Rafique, Sobia Tabassum, Rizwan Akram
Chemical Papers.2020; 74(8): 2591. CrossRef Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
S. Capellero, J. Erriquez, C. Melano, G. Mesiano, S. Genta, A. Pisacane, G. Mittica, E. Ghisoni, M. Olivero, M. F. Di Renzo, M. Aglietta, D. Sangiolo, G. Valabrega
Scientific Reports.2020;[Epub] CrossRef Role of lncRNAHCP5/microRNA-525–5p/PRC1 crosstalk in the malignant behaviors of ovarian cancer cells
Ling Wang, Miao He, Li Fu, Yuemei Jin
Experimental Cell Research.2020; 394(1): 112129. CrossRef Immune profiling reveals prognostic genes in high-grade serous ovarian cancer
Yong Wu, Lingfang Xia, Ping Zhao, Yu Deng, Qinhao Guo, Jun Zhu, Xiaojun Chen, Xingzhu Ju, Xiaohua Wu
Aging.2020; 12(12): 11398. CrossRef A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer
Daniel C. Beachler, Francois-Xavier Lamy, Leo Russo, Devon H. Taylor, Jade Dinh, Ruihua Yin, Aziza Jamal-Allial, Samuel Dychter, Stephan Lanes, Patrice Verpillat
Journal of Ovarian Research.2020;[Epub] CrossRef Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior
Yanxin Wang, Yi-Shiou Chiou, Qing-Yun Chong, Mengyi Zhang, Kanchuragoppal S. Rangappa, Lan Ma, Tao Zhu, Alan Prem Kumar, Ruby Yun-Ju Huang, Vijay Pandey, Basappa, Peter E. Lobie
ACS Pharmacology & Translational Science.2020; 3(6): 1083. CrossRef Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer
Domenica Lorusso, Valentina Ceni, Margherita Muratore, Vanda Salutari, Camilla Nero, Antonella Pietragalla, Francesca Ciccarone, Vittoria Carbone, Gennaro Daniele, Giovanni Scambia
Expert Opinion on Emerging Drugs.2020; 25(4): 445. CrossRef Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination
Ricardo Roque, Filipa Costa Sousa, Margarida Figueiredo-Dias
Oncology Reviews.2020;[Epub] CrossRef SRT2183 impairs ovarian cancer by facilitating autophagy
Tingting Sun, Yanfen Hu, Weipeng He, Yuru Shang, Xiaohong Yang, Liyun Gong, Xianbin Zhang, Peng Gong, Guofen Yang
Aging.2020; 12(23): 24208. CrossRef Monoclonal antibody against human Tim‐3 enhances antiviral immune response
Ge Li, Chunmei Hou, Shuaijie Dou, Jiacheng Zhang, Yanling Zhang, Yiqiong Liu, Zhiding Wang, He Xiao, Renxi Wang, Guojiang Chen, Yan Li, Jiannan Feng, Beifen Shen, Gencheng Han
Scandinavian Journal of Immunology.2019;[Epub] CrossRef Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways
Xi Zhang, Guoqing Hou, Andong Liu, Hui Xu, Yang Guan, Yaosong Wu, Jie Deng, Xuan Cao
Cell Death & Disease.2019;[Epub] CrossRef Long Noncoding RNA LINC01133 Confers Tumor-Suppressive Functions in Ovarian Cancer by Regulating Leucine-Rich Repeat Kinase 2 as an miR-205 Sponge
Min Liu, Cuiping Shen, Changxiu Wang
The American Journal of Pathology.2019; 189(11): 2323. CrossRef Role of lncRNA‑ATB in ovarian cancer and its mechanisms of action
Donglan Yuan, Xiaofang Zhang, Yinling Zhao, Hua Qian, Hezhu Wang, Cuiqin He, Xia Liu, Ting Guo, Mei Lin, Hong Yu, Jun Ye
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer
Stephen Shang, Jiekun Yang, Amir A. Jazaeri, Alexander James Duval, Turan Tufan, Natasha Lopes Fischer, Mouadh Benamar, Fadila Guessous, Inyoung Lee, Robert M. Campbell, Philip J. Ebert, Tarek Abbas, Charles N. Landen, Analisa Difeo, Peter C. Scacheri, Ma
Cancer Research.2019; 79(18): 4599. CrossRef WITHDRAWN: Addition of targeted agents to chemotherapy for persistent or recurrent ovarian cancer: a meta-analysis of randomized controlled trials
Xiao Li, Yuchan Mao, Qiwen Wu, Yuanyuan Liu, Qianqian Wu, Binghuan Wen
Critical Reviews in Oncology/Hematology.2018;[Epub] CrossRef
|